ProQR Therapeutics BV
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.6
- Today's High:
- $1.63
- Open Price:
- $1.6
- 52W Low:
- $0.722
- 52W High:
- $3.85
- Prev. Close:
- $1.6
- Volume:
- 31740
Company Statistics
- Market Cap.:
- $129.50 million
- Book Value:
- 0.64
- Revenue TTM:
- $4.48 million
- Operating Margin TTM:
- -1116.47%
- Gross Profit TTM:
- $4.80 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -19.13%
- Return on Equity TTM:
- -78.17%
Company Profile
ProQR Therapeutics BV had its IPO on 2014-09-18 under the ticker symbol PRQR.
The company operates in the Healthcare sector and Biotechnology industry. ProQR Therapeutics BV has a staff strength of 130 employees.
Stock update
Shares of ProQR Therapeutics BV opened at $1.6 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.6 - $1.63, and closed at $1.6.
This is a 0% increase from the previous day's closing price.
A total volume of 31,740 shares were traded at the close of the day’s session.
In the last one week, shares of ProQR Therapeutics BV have increased by +0.63%.
ProQR Therapeutics BV's Key Ratios
ProQR Therapeutics BV has a market cap of $129.50 million, indicating a price to book ratio of 1.7016 and a price to sales ratio of 29.2419.
In the last 12-months ProQR Therapeutics BV’s revenue was $4.48 million with a gross profit of $4.80 million and an EBITDA of $-49274000. The EBITDA ratio measures ProQR Therapeutics BV's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ProQR Therapeutics BV’s operating margin was -1116.47% while its return on assets stood at -19.13% with a return of equity of -78.17%.
In Q2, ProQR Therapeutics BV’s quarterly earnings growth was a positive 0% while revenue growth was a positive 20.8%.
ProQR Therapeutics BV’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.8 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ProQR Therapeutics BV’s profitability.
ProQR Therapeutics BV stock is trading at a EV to sales ratio of 9.8438 and a EV to EBITDA ratio of -0.5018. Its price to sales ratio in the trailing 12-months stood at 29.2419.
ProQR Therapeutics BV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $147.99 million
- Total Liabilities
- $22.98 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $294000
- Dividend Payout Ratio
- 0%
ProQR Therapeutics BV ended 2024 with $147.99 million in total assets and $0 in total liabilities. Its intangible assets were valued at $147.99 million while shareholder equity stood at $51.79 million.
ProQR Therapeutics BV ended 2024 with $0 in deferred long-term liabilities, $22.98 million in other current liabilities, 3370000.00 in common stock, $-391932000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $128.56 million and cash and short-term investments were $128.56 million. The company’s total short-term debt was $4,254,000 while long-term debt stood at $3.58 million.
ProQR Therapeutics BV’s total current assets stands at $131.15 million while long-term investments were $621000.00 and short-term investments were $0. Its net receivables were $400000.00 compared to accounts payable of $119000.00 and inventory worth $0.
In 2024, ProQR Therapeutics BV's operating cash flow was $0 while its capital expenditure stood at $294000.
Comparatively, ProQR Therapeutics BV paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.6
- 52-Week High
- $3.85
- 52-Week Low
- $0.722
- Analyst Target Price
- $3.95
ProQR Therapeutics BV stock is currently trading at $1.6 per share. It touched a 52-week high of $3.85 and a 52-week low of $3.85. Analysts tracking the stock have a 12-month average target price of $3.95.
Its 50-day moving average was $1.6 and 200-day moving average was $2.19 The short ratio stood at 3.63 indicating a short percent outstanding of 0%.
Around 1917.6% of the company’s stock are held by insiders while 3897.3% are held by institutions.
Frequently Asked Questions About ProQR Therapeutics BV
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.